Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence,Clinical Stage,and Alzheimer’s Disease Biomarkers
Restricted accessResearch articleFirst published online January 12, 2016
Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence,Clinical Stage,and Alzheimer’s Disease Biomarkers
Biomarkers for Alzheimer’s disease (AD) are vital for disease detection in the clinical setting. Discovered in our laboratory, activity-dependent neuroprotective protein (ADNP) is essential for brain formation and linked to cognitive functions. Here, we revealed that blood borne expression of ADNP and its paralog ADNP2 is correlated with premorbid intelligence, AD pathology, and clinical stage. Age adjustment showed significant associations between: 1) higher premorbid intelligence and greater serum ADNP, and 2) greater cortical amyloid and lower ADNP and ADNP2 mRNAs. Significant increases in ADNP mRNA levels were observed in patients ranging from mild cognitive impairment (MCI) to AD dementia. ADNP2 transcripts showed high correlation with ADNP transcripts, especially in AD dementia lymphocytes. ADNP plasma/serum and lymphocyte mRNA levels discriminated well between cognitively normal elderly, MCI, and AD dementia participants. Measuring ADNP blood-borne levels could bring us a step closer to effectively screening and tracking AD.
ChungSJ, LeeJH, KimSY, YouS, KimMJ, LeeJY, KohJ (2013) Association of GWAS top hits with late-onset Alzheimer disease in Korean population. Alzheimer Dis Assoc Disord27, 250–257.
2.
SwerdlowRH, CorderEH (2012) For Alzheimer disease GWAS, pulling needles from the haystack is just the first step. Neurology79, 204–205.
3.
TostoG, ReitzC (2013) Genome-wide association studies in Alzheimer’s disease: A review. Curr Neurol Neurosci Rep13, 381.
4.
LehmannS, DelabyC, TouchonJ, HirtzC, GabelleA (2013) Biomarkers of Alzheimer’s disease: The present and the future. Rev Neurol (Paris)169, 719–723.
BassanM, ZamostianoR, DavidsonA, PinhasovA, GiladiE, PerlO, BassanH, BlatC, GibneyG, GlaznerG, BrennemanDE, GozesI (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J Neurochem72, 1283–1293.
11.
ZamostianoR, PinhasovA, GelberE, SteingartRA, SeroussiE, GiladiE, BassanM, WollmanY, EyreHJ, MulleyJC, BrennemanDE, GozesI (2001) Cloning and characterization of the human activity-dependent neuroprotective protein. J Biol Chem276, 708–714.
12.
PinhasovA, MandelS, TorchinskyA, GiladiE, PittelZ, GoldsweigAM, ServossSJ, BrennemanDE, GozesI (2003) Activity-dependent neuroprotective protein: A novel gene essential for brain formation. Brain Res Dev Brain Res144, 83–90.
13.
MandelS, RechaviG, GozesI (2007) Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev Biol303, 814–824.
14.
MalishkevichA, AmramN, Hacohen-KleimanG, MagenI, GiladiE, GozesI (2015) Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer’s pathologies. Transl Psychiatry5, e501.
15.
Vulih-ShultzmanI, PinhasovA, MandelS, GrigoriadisN, TouloumiO, PittelZ, GozesI (2007) Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther323, 438–449.
16.
Fernandez-MontesinosR, TorresM, Baglietto-VargasD, GutierrezA, GozesI, VitoricaJ, PozoD (2010) Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer’s disease. J Mol Neurosci41, 114–120.
17.
SchirerY, MalishkevichA, OphirY, LewisJ, GiladiE, GozesI (2014) Novel marker for the onset of frontotemporal dementia: Early increase in activity-dependent neuroprotective protein (ADNP) in the face of tau mutation. PLoS One9, e87383.
18.
GozesI, IramT, MaryanovskyE, ArvivC, RozenbergL, SchirerY, GiladiE, Furman-AssafS (2014) Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide). J Alzheimers Dis40(Suppl 1), S23–S36.
19.
GozesI, YeheskelA, Pasmanik-ChorM (2015) Activity-dependent neuroprotective protein (ADNP): A case study for highly conserved chordata-specific genes shaping the brain and mutated in cancer. J Alzheimers Dis45, 57–73.
20.
KushnirM, DresnerE, MandelS, GozesI (2008) Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress. J Neurochem105, 537–545.
21.
DresnerE, AgamG, GozesI (2011) Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: Deregulation in schizophrenia. Eur Neuropsychopharmacol21, 355–361.
22.
DresnerE, MalishkevichA, ArvivC, Leibman BarakS, AlonS, OfirR, GothilfY, GozesI (2012) Novel evolutionary-conserved role for the activity-dependent neuroprotective protein (ADNP) family that is important for erythropoiesis. J Biol Chem287, 40173–40185.
23.
Merenlender-WagnerA, MalishkevichA, ShemerZ, UdawelaM, GibbonsA, ScarrE, DeanB, LevineJ, AgamG, GozesI (2015) Autophagy has a key role in the pathophysiology of schizophrenia. Mol Psychiatry20, 126–132.
24.
YangMH, YangYH, LuCY, JongSB, ChenLJ, LinYF, WuSJ, ChuPY, ChungTW, TyanYC (2012) Activity-dependent neuroprotector homeobox protein: A candidaterotein identified in serum as diagnostic biomarker for Alzheimer’s disease. J Proteomics75, 3617–3629.
25.
MorrisJC (1993) The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology43, 2412–2414.
26.
FolsteinMF, FolsteinSE, McHughPR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
27.
WechslerD (1987) Manual for the Wechsler Memory Scale-Revised, The Psychological Corporation, San Antonio,TX.
28.
YesavageJA, BrinkTL, RoseTL, LumO, HuangV, AdeyM, LeirerVO (1982) Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res17, 37–49.
29.
NelsonHE, O’ConnellA (1978) Dementia: The estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex14, 234–244.
30.
GrowdonME, SchultzAP, DagleyAS, AmariglioRE, HeddenT, RentzDM, JohnsonKA, SperlingRA, AlbersMW, MarshallGA (2015) Odor identification and Alzheimer’s disease biomarkers in clinically normal elderly. Neurology84, 2153–2160.
31.
DonovanNJ, HsuDC, DagleyAS, SchultzAP, AmariglioRE, MorminoEC, OkerekeOI, RentzDM, JohnsonKA, SperlingRA, MarshallGA (2015) Depressive symptoms and biomarkers of Alzheimer’s disease in cognitively normal older adults. J Alzheimers Dis46, 63–73.
32.
MorminoE, BetenskyR, HeddenT, SchultzA, WardA, HujibersW, RentzD, JohnsonK, SperlingR (2014) Amyloid and APOE ɛ4 interact to influence short-term decline in preclinical Alzheimer disease. Neurology82, 1760–1767.
33.
BeckerJ, HeddenT, CarmasinJ, MayeJ, ReimanE, RentzD, PutchaD, FischiB, GreveD, MarshallG, SallowayS, MarksD, BucknerR, SperlingR, JohnsonK (2011) Amyloid-beta associated cortical thinning in clinically normal elderly. Ann Neurol69, 1032–1042.
PriceJC, KlunkWE, LoprestiBJ, LuX, HogeJA, ZiolkoSK, HoltDP, MeltzerCC, DeKoskyST, MathisCA (2005) Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab25, 1528–1547.
36.
LandauS, HarveyD, MadisonC, KoeppeR, ReimanE, FosterN, WeinerM, JagustW (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging32, 1207–1218.
37.
MarshallGA, LoriusN, LocascioJJ, HymanBT, RentzDM, JohnsonKA, SperlingRA (2014) Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer disease spectrum. J Alzheimers Dis41, 719–728.
38.
OlssonA, VandersticheleH, AndreasenN, De MeyerG, WallinA, HolmbergB, RosengrenL, VanmechelenE, BlennowK (2005) Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem51, 336–345.
39.
FaganAM, MintunMA, MachRH, LeeSY, DenceCS, ShahAR, LaRossaGN, SpinnerML, KlunkWE, MathisCA, DeKoskyST, MorrisJC, HoltzmanDM (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol59, 512–519.
40.
TapiolaT, AlafuzoffI, HerukkaSK, ParkkinenL, HartikainenP, SoininenH, PirttilaT (2009) Cerebrospinal fluid beta-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol66, 382–389.
41.
OzS, KapitanskyO, Ivashco-PachimaY, MalishkevichA, GiladiE, SkalkaN, Rosin-ArbesfeldR, MittelmanL, SegevO, HirschJA, GozesI (2014) The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol Psychiatry19, 1115–1124.
42.
FurmanS, SteingartRA, MandelS, HauserJM, BrennemanDE, GozesI (2004) Subcellular localization and secretion of activity-dependent neuroprotective protein in astrocytes. Neuron Glia Biol1, 193–199.
43.
VandeweyerG, HelsmoortelC, Van DijckA, Vulto-van SilfhoutAT, CoeBP, BernierR, GerdtsJ, RoomsL, van den EndeJ, BakshiM, WilsonM, NordgrenA, HendonLG, AbdulrahmanOA, RomanoC, de VriesBB, KleefstraT, EichlerEE, Van der AaN, KooyRF (2014) The transcriptional regulator ADNP links the BAF (SWI/SNF) complexes with autism. Am J Med Genet C Semin Med Genet166C, 315–326.
44.
AboonqMS, VasiliouSA, HaddleyK, QuinnJP, BubbVJ (2012) Activity-dependent neuroprotective protein modulates its own gene expression. J Mol Neurosci46, 33–39.
45.
SternY (2002) What is cognitive reserve? Theory and research application of the reserve concept. J Int Neuropsychol Soc8, 448–460.
46.
RentzDM, LocascioJJ, BeckerJA, MoranEK, EngE, BucknerRL, SperlingRA, JohnsonKA (2010) Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol67, 353–364.
47.
BraitchM, KawabeK, NyirendaM, GillesLJ, RobinsRA, GranB, MurphyS, ShoweL, ConstantinescuCS (2009) Expression of activity-dependent neuroprotective protein in the immune system: Possible functions and relevance to multiple sclerosis. Neuroimmunomodulation17, 120–125.
48.
GozesI, StewartA, MorimotoB, FoxA, SutherlandK, SchmechelD (2009) Addressing Alzheimer’s disease tangles: From NAP to AL-108. Curr Alzheimer Res6, 455–460.
